Corona Remedies Revenue and Competitors
Estimated Revenue & Valuation
- Corona Remedies's estimated annual revenue is currently $336.7M per year.
- Corona Remedies's estimated revenue per employee is $201,000
Employee Data
- Corona Remedies has 1675 Employees.
- Corona Remedies grew their employee count by 8% last year.
Corona Remedies's People
Name | Title | Email/Phone |
---|
Corona Remedies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Corona Remedies?
N/A
Total Funding
1675
Number of Employees
$336.7M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Corona Remedies News
2022-04-06 - Fatigue after COVID is way more than just feeling tired. 5 tips on what to do about it
So, understandably, there has been concern around the coronavirus potentially triggering chronic fatigue syndrome. Read more: Explainer: what is...
2022-03-30 - Effect of Early Treatment with Ivermectin among Patients with Covid ...
Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19)...
2022-03-22 - Treatments for coronavirus (COVID-19)
The NHS is offering antibody and antiviral treatments to people with coronavirus (COVID-19) who are at highest risk of becoming seriously ill. The treatments...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $422.9M | 1678 | N/A | N/A |
#2 | $493.6M | 1679 | 21% | N/A |
#3 | $75M | 1685 | 5% | N/A |
#4 | $495.4M | 1685 | N/A | N/A |
#5 | $545.8M | 1692 | 9% | $875M |